The aim: The purpose of the research is to study the understanding of student pharmaceutical youth the eating behavior in the context of the EBW and obesity.
Materials and methods: The material of the study was anonymous questionnaire survey the students of the pharmaceutical faculties from Ukraine.
Results: The results of the questionnaire were analyzed using methods of statistics, comparison and generalization. Almost 9 out of 10 respondents from both universities
consider the reason of obesity a sedentary lifestyle and poor nutrition, and the most effective way to treat it is physical activity, though only 36.3% and 28.4% of students of
the corresponding samples have it constantly.
Conclusions: The questionnaire showed a lack of eating behavior, of their knowledge of the basic issues of the EBW and obesity, as well as differences in personal perception
and the desire for the practical implementation of queries regarding the weight of their body that may further affect the professional ability of young specialists in influencing
the processes of formation and improving the quality of their lives and patients’ lives.

Ischemic stroke belongs to the leading causes of death and disability in the world and Ukraine. The surviving rates depend on the quality of the provided medical care. The research aimed to analyze the quality of medical care related to pharmacotherapy of ischemic stroke. The clinical indicators for quality are the quantitative or qualitative indicants that have evidence or consensus of direct influence on it. Six of them relate to acute ischemic stroke
pharmacotherapy (namely, thrombolytic, antiplatelet, anticoagulant, and lipid-lowering agents use at different stages of hospital stay) and were investigated in this retrospective analysis of 151 patients’ medical records of one of the specialized hospital departments in Lviv city. The clinical indicators for quality of medical care showed that pharmacological treatment using antithrombotics (antiplatelets and anticoagulants) at the admission to the hospital
corresponded to standards and quality was defined as high with rates of 65.6% and 85.4%. At discharge, the indicator analysis of pharmacotherapy revealed existing problems for antithrombotic (2 indicators) and lipid-lowering (1 indicator) pharmacotherapy with rates of 33.3% and 47.7%.
The outcomes concluded the existence of problems related to pharmacotherapy. The complex of three algorithms was introduced to improve the quality of medical care. 

Abstract

Diabetic retinopathy (DR) is the most significant and common cause of visual impairment in diabetes patients. The aim of the study was to enhance the understanding of the pathogenesis of DR associated with metabolic syndrome (MS) and elucidate the role of cellular and humoral immunity factors. The study included 130 patients. Group 1 comprised 70 patients diagnosed with DR and insulin-dependent type 2 diabetes against the background of MS. Group 2 included 60 patients diagnosed with DR and non-insulin-dependent type 2 diabetes associated with MS. The immunological analysis focused on evaluating subpopulations of blood lymphocytes using flow cytometry; systemic inflammation markers, such as CRP, specific IgA, IgM, and IgG, cytokines measured by ELISA. Significant changes in immune status were observed in patients with DR associated with MS, depending on diabetes compensation. In Group 1 patients with DR, more pronounced alterations in the T-cell immunity pathway were observed, including T-cell immunodeficiency accompanied by the activation of killer and B-cell immunity, compared to non-insulin-dependent patients. Both groups exhibited type IV hypersensitivity reactions. Elevated CRP level was detected only in insulin-dependent patients with DR. An analysis of the immune parameters indicated predominant activation of the specific humoral immunity pathway, suggesting chronicity of the condition. Non-insulin-dependent patients showed significant activation of mucosal humoral defenses and early humoral protective mechanisms. The data revealed more pronounced changes in specific humoral immunity markers, such as immunoglobulins, compared to systemic inflammation markers like CRP.